Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 3,499 shares at $12.83 ($45K) on 2024-05-02, disclosed to the SEC on 2024-05-02.
Scheduled sale ($45k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| NRIX | SELL | 2026-05-05 | $233K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |